Frontlight ResearchEarly access
Lung cancer trials in Greece
66 of 70 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 17 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleA Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
- Where
- Athens, Efkarpia, Larissa, Thessaloniki
- Age
- 18 years and over
- People
- 850 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07361497 · EU 2025-523576-23-00 - Phase 3Taking peopleA Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Where
- Athens, Heraklion, Patras, Thessaloniki
- Age
- 18 years and over
- People
- 1,264 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06119581 · EU 2023-503412-33-00 - Phase 3Active, not recruitingA Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Where
- Athens, Larissa, Thessaloniki
- Age
- 18 years and over
- People
- 444 worldwide
- Run by
- Bayer
See details and how to joinNCT06452277 · EU 2024-511319-91-00 - Phase 3Taking peopleStudy of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- Where
- Athens, Heraklion, Larissa, Pátrai, Thessaloniki
- Age
- 18 years and over
- People
- 700 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06890598 · EU 2024-512302-25-00 - Phase 2Taking peopleA Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Where
- Athens, Pireas, Thessaloniki
- Age
- 18 years and over
- People
- 480 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06667076 · EU 2025-520730-28-00 - Phase 3Not yet taking people in GreeceClinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy
- Where
- Athens, Ioannina, Patras, Pylaia, Thessaloniki
- Age
- 18 years to 90 years
- People
- 507 worldwide
- Run by
- ImmunityBio, Inc.
See details and how to joinNCT06745908 · EU 2025-521221-32-00 - Phase 3Taking peopleStudy to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
- Where
- Athens, Thessaloniki
- Age
- 18 years and over
- People
- 480 worldwide
- Run by
- ArriVent BioPharma, Inc.
See details and how to joinNCT07185997 - Phase 3Not yet taking people in GreeceBeamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
- Where
- Athens, Chaïdári
- Age
- 18 years and over
- People
- 400 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07195695 · EU 2025-521284-12-00 - Phase 2/3Taking peoplePhase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- Where
- Athens, Chaïdári, Heraklion, Kifissia, Larissa, Pireas, Thessaloniki
- Age
- 18 years and over
- People
- 626 worldwide
- Run by
- Mirati Therapeutics Inc.
See details and how to joinNCT04613596 · EU 2023-508922-83-00 - Phase 3Taking peopleA Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Where
- Athens, Pireas
- Age
- 18 years and over
- People
- 768 worldwide
- Run by
- AbbVie
See details and how to joinNCT04928846 · EU 2023-505749-14-00 - Phase 3Taking peopleA Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- Where
- Athens, Larissa
- Age
- 18 years and over
- People
- 630 worldwide
- Run by
- Mirati Therapeutics Inc.
See details and how to joinNCT06875310 · EU 2024-515698-85-00 - Phase 3Taking peopleA phase 3 trial comparing a therapeutic cancer vaccine OSE2101 to chemotherapy docetaxel in patients with metastatic Non-Small Cell Lung Cancer (NSCLC) after immunotherapy failure.
- Where
- Athens, Efkarpia, Heraklion, Kifissia, Larissa, Patras, Pireas, Thessaloniki
- Age
- 18 years and over
- People
- 340 worldwide
- Run by
- OSE Immunotherapeutics
See details and how to join2023-509340-10-00 - Phase 3Taking peopleStudy of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
- Where
- Athens, Efkarpia, Larissa, Patras, Pireas, Thessaloniki
- Age
- 18 years and over
- People
- 686 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06899126 · EU 2024-515658-26-00 - Phase 3Taking peopleStudy of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
- Where
- Athens, Larissa, Rio, Thessaloniki
- Age
- 18 years and over
- People
- 695 worldwide
- Run by
- Gilead Sciences
See details and how to joinNCT06801834 - Phase 3Taking peopleA Study to Test How Well ZL-1310 may Work Compared to Therapies Selected by the Investigator in Treating Patients with Relapsed Small Cell Lung Cancer
- Where
- Athens, Chaïdári, Heraklion, Larissa, Patras, Pireas, Thessaloniki
- Age
- 18 years and over
- People
- 263 worldwide
- Run by
- Zai Lab (US) LLC
See details and how to join2025-522818-23-00 - Phase 1/2Taking peopleStudy of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
- Where
- Athens, Thessaloniki
- Age
- 18 years and over
- People
- 616 worldwide
- Run by
- Revolution Medicines, Inc.
See details and how to joinNCT06162221 · EU 2025-521147-21-00 - Phase 2Active, not recruitingA Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
- Where
- Athens, Thessaloniki
- Age
- 18 years and over
- People
- 90 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06731907 · EU 2024-515772-12-00 - Phase 3Taking peopleA Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
- Where
- Athens, Rio, Thessaloniki
- Age
- 18 years and over
- People
- 480 worldwide
- Run by
- Zai Lab (Shanghai) Co., Ltd.
See details and how to joinNCT07218146 - Phase 2/3Not yet taking people in GreeceIZABRIGHT-Lung01: Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy
- Where
- Athens, Chaïdári, Thessaloniki
- Age
- 18 years and over
- People
- 173 worldwide
- Run by
- Bristol-Myers Squibb Services Unlimited Company
See details and how to join2025-521908-22-00 - Phase 3Not yet taking people in GreeceA Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
- Where
- Athens, Pireas, Thessaloniki
- Age
- 18 years and over
- People
- 360 worldwide
- Run by
- Taiho Oncology, Inc.
See details and how to joinNCT07128199 · EU 2025-521775-31-00 - Phase 3Taking peopleSymbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Where
- Athens, Cholargos, Heraklion, Larissa, Patras, Pireas, Thessaloniki
- Age
- 18 years and over
- People
- 1,410 worldwide
- Run by
- Pfizer
See details and how to joinNCT07222566 · EU 2025-523461-17-01 - Phase 3Taking peopleA Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants with Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Where
- Athens, Larissa, Thessaloniki
- Age
- 18 years and over
- People
- 282 worldwide
- Run by
- F. Hoffmann-La Roche AG
See details and how to join2024-518365-10-00 - Phase 3Taking peopleEffect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer
- Where
- Athens, Pireas, Thessaloniki
- Age
- 18 years and over
- People
- 120 worldwide
- Run by
- Pharmacosmos A/S
See details and how to joinNCT07473128 · EU 2025-525026-35-00 - Phase 1/2Taking peopleA Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
- Where
- Athens, Efkarpia
- Age
- 18 years and over
- People
- 140 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07286149 · EU 2024-512248-47-00 - Phase 3Taking peopleNeladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
- Where
- Athens, Larissa, Maroussi, Thessaloniki
- Age
- 18 years and over
- People
- 450 worldwide
- Run by
- Nuvalent Inc.
See details and how to joinNCT06765109 · EU 2024-517553-26-00